Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF-aα, but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patients

Arthritis Research and Therapy

Volumn 17, Issue 1, 2015, Pages

  Fleischer, Vanessa ^a   Sieber, Julia ^a   Fleischer, Sarah J ^b   Shock, Anthony ^c   Heine, Guido ^a   Daridon, Capucine ^b   Dörner, Thomas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^c UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; CD22 ANTIGEN; EPRATUZUMAB; INTERLEUKIN 10; INTERLEUKIN 6; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; CYTOKINE; IL10 PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLOOD DONOR; DRUG EFFECTS; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; B-LYMPHOCYTES; BLOOD DONORS; CYTOKINES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-10; INTERLEUKIN-6; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84937213929     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-015-0686-2     Document Type: Article

References (16)

1. Anolik JH. B cell biology and dysfunction in SLE. Bull NYU Hosp Jt Dis. 2007;65:182-6.
2. Dörner T, Jacobi AM, Lee J, Lipsky PE. Abnormalities of B cell subsets in patients with systemic lupus erythematosus. J Immunol Methods. 2011;363:187-97.
3. Carnahan J, Wang P, Kendall R, Chen C, Hu S, Boone T, et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res. 2003;9:3982S-90S.
4. Jacobi AM, Goldenberg DM, Hiepe F, Radbruch A, Burmester GR, Dorner T. Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann Rheum Dis. 2008;67:450-7.
5. Daridon C, Blassfeld D, Reiter K, Mei HE, Giesecke C, Goldenberg DM, et al. Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. Arthritis Res Ther. 2010;12:R204.
6. 2+ flux upon activation. Arthritis Rheum. 2013;65:770-9.
7. Macauley MS, Crocker PR, Paulson JC. Siglec-mediated regulation of immune cell function in disease. Nat Rev Immunol. 2014;14:653-66.
8. Fillatreau S. Cytokine-producing B cells as regulators of pathogenic and protective immune responses. Ann Rheum Dis. 2013;72:ii80-4.
9. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
10. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005;353:2550-8.
11. Mei HE, Yoshida T, Sime W, Hiepe F, Thiele K, Manz RA, et al. Blood-borne human plasma cells in steady state are derived from mucosal immune responses. Blood. 2009;113:2461-9.
12. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. B cells regulate autoimmunity by provision of IL-10. Nat Immunol. 2002;3:944-50.
13. Iwata Y, Matsushita T, Horikawa M, Dilillo DJ, Yanaba K, Venturi GM, et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood. 2011;117:530-41.
14. Gao N, Dresel J, Eckstein V, Gellert R, Storch H, Venigalla RK, et al. Impaired suppressive capacity of activation-induced regulatory B cells in systemic lupus erythematosus. Arthritis Rheumatol. 2014;18:2849.
15. Shen P, Roch T, Lampropoulou V, O'Connor RA, Stervbo U, Hilgenberg E, et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature. 2014;507:366-70.
16. + T-cell activation in vitro. Eur J Immunol. 2010;40:2686-91.